NCT05445440View on ClinicalTrials.gov

A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

November 17, 2022

Study Completion Date

November 23, 2022

Conditions
Healthy Participants
Interventions
DRUG

Methotrexate

Specified dose on specified days

DRUG

Leucovorin

Specified dose on specified days

DRUG

BMS-986371

Specified dose on specified days

DRUG

Sulfasalazine

Specified dose on specified days

Trial Locations (1)

33126

Quotient Sciences Miami, Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05445440 - A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine | Biotech Hunter | Biotech Hunter